Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
Coya Therapeutics, Inc.
organization3 mentionslast seen Oct 14, 2026
A biopharmaceutical company developing immunotherapies for amyotrophic lateral sclerosis.
Relationships 2
Relationship
Coya Therapeutics, Inc.developsCOYA 302
99% confidence3 supporting mentions
Either name opens that entity’s relationships.
Sources 3
- filingSEC EDGAROct 14, 2026Coya Therapeutics, Inc. 8-K: Item 8.01: Other Events
Coya Therapeutics, Inc. issued a press release announcing plans to initiate an open-label extension of the Phase 2/3 ALSTARS Trial evaluating COYA 302
- filingSEC EDGAROct 5, 2026Coya Therapeutics, Inc. 8-K: Item 8.01: Other Events
COYA 302, the Company's combination of proprietary low-dose IL-2 and CTLA-4 Ig
- filingSEC EDGARSep 15, 2026Coya Therapeutics, Inc. 8-K: Item 8.01: Other Events
the Company's combination of proprietary low-dose IL-2 and CTLA-4 Ig